YOVIX Performance — Yorktown Small Cap Fund, Institutional Class
Data updated: 2026-09-29
YOVIX returned +6.72% year to date and +7.16% over one year to Jul 2026. Annualised returns are +7.82% over 3 years and +2.45% over 5 years. The fund trailed its US Small Growth category average: $100 invested three years ago grew to $125, against $142 for the category, and to $107 over one year, against $123. Volatility over the past three years was 17.74% a year. In the 12 months to Jul 2026 the fund took in a net $3.2M, and assets reached $36.03M.
YOVIX Growth of $100
What $100 invested in Yorktown Small Cap Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Small Growth category average over the same months.
| Period | YOVIX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $107 | $123 |
| 3 years (Aug 2023 – Jul 2026) | $125 | $142 |
| 5 years (Aug 2021 – Jul 2026) | $113 | $121 |
| Since data start (Aug 2019 – Jul 2026) | $203 | $189 |
YOVIX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +6.72% |
| 1 year | +7.16% |
| 3 years (annualised) | +7.82% |
| 5 years (annualised) | +2.45% |
YOVIX Annual Returns
Calendar-year total returns of Yorktown Small Cap Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +6.72% |
| 2025 | +9.64% |
| 2024 | +6.01% |
| 2023 | +14.19% |
| 2022 | −25.18% |
| 2021 | +24.58% |
| 2020 | +53.38% |
| 2019 (Aug–Dec) | +0.01% |
YOVIX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.4% | −2.2% | −6.8% | +12.5% | +4.4% | +6.0% | −8.1% | — | — | — | — | — |
| 2025 | +5.5% | −3.9% | −5.9% | +0.6% | +7.4% | +4.5% | +1.4% | +3.7% | +2.7% | −0.3% | −3.7% | −1.8% |
| 2024 | −0.3% | +4.9% | +4.1% | −6.1% | +3.7% | −1.9% | +2.2% | −1.3% | +0.7% | −0.4% | +9.3% | −7.8% |
| 2023 | +9.2% | 0.0% | −3.1% | −4.2% | −0.8% | +8.5% | +3.5% | −3.0% | −4.1% | −5.2% | +5.7% | +8.5% |
| 2022 | −10.8% | +2.8% | −0.9% | −11.9% | −1.1% | −9.0% | +10.4% | −1.1% | −7.4% | +8.3% | +2.6% | −7.6% |
| 2021 | +9.6% | +1.6% | −1.1% | +2.3% | −1.5% | +4.8% | +0.5% | +3.7% | −3.5% | +6.9% | −2.3% | +1.9% |
| 2020 | 0.0% | −0.1% | −0.2% | +0.2% | +6.5% | +3.9% | +8.4% | +3.4% | −2.8% | −0.2% | +15.9% | +10.2% |
| 2019 | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
YOVIX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 17.74%
- 3-year Sharpe ratio: 0.19 (vs 4.5% risk-free rate)
- Best month: +12.51% (Apr 2026)
- Worst month: −8.11% (Jul 2026)
YOVIX Fund Flows
Monthly money in and out of Yorktown Small Cap Fund, from SEC Form N-PORT.
- 12-month net flow: $3.2M
- 12-month gross sales (incl. reinvestments): $9.0M
- Sales ÷ redemptions: 1.54×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $138K | $289K | −$151K |
| Jun 2026 | $325K | $413K | −$89K |
| May 2026 | $298K | $493K | −$195K |
| Apr 2026 | $433K | $423K | $10K |
| Mar 2026 | $192K | $476K | −$284K |
| Feb 2026 | $524K | $355K | $169K |
| Jan 2026 | $796K | $244K | $552K |
| Dec 2025 | $484K | $951K | −$467K |
| Nov 2025 | $481K | $74K | $408K |
| Oct 2025 | $603K | $163K | $440K |
| Sep 2025 | $4.5M | $429K | $4.1M |
| Aug 2025 | $237K | $1.6M | −$1.3M |
YOVIX Assets Under Management
Net assets of Yorktown Small Cap Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $36.03M |
| 2026-04-30 | $35.87M |
| 2026-01-31 | $35.15M |
| 2025-10-31 | $35.84M |
| 2025-07-31 | $30.78M |
| 2025-04-30 | $25.79M |
| 2025-01-31 | $31.02M |
| 2024-10-31 | $29.20M |
| 2024-07-31 | $28.61M |
| 2024-04-30 | $30.30M |
| 2024-01-31 | $30.97M |
| 2023-10-31 | $27.92M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.